ArticleInternational journal of general medicine2025
A Six-Gene Mitochondrial Signature Predicts Prognosis in Dedifferentiated Thyroid Cancer.
Article in International journal of general medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Dedifferentiated thyroid cancer (DDTC) is a highly malignant, infiltrative neoplasm. Studies confirm mitochondrial (MD) dysfunction links to DDTC's aggressiveness and treatment resistance via regulating energy metabolism reprogramming, exacerbating oxidative stress, and mediating apoptotic resistance. This study explored the role of MD related genes (MDRGs) in DDTC prognosis to inform prognostic evaluation and targeted therapy. Methods: In this study, DDTC prognostic genes were identified through integrated analyses, including differential analysis, weighted gene co-expression network analysis (WGCNA), univariate Cox regression, and machine Learning. Subsequently, risk model and nomogram were constructed. Functional enrichment analysis explored prognosis-related pathways, while immune infiltration analysis revealed distinct immune cell infiltration patterns between high- and low-risk groups. Additionally, drug sensitivity analysis and drug prediction identified potential therapeutic targets for DDTC. Finally, prognostic gene expression was validated using quantitative real-time polymerase chain reaction (qRT-PCR). Results: A total of 6 MDRGs were obtained. Both risk model and nomogram demonstrated robust predictive performance. Furthermore, high-risk group was closely associated with DDTC prognosis, particularly involving pathways such as cytokine receptor interaction and biological processes like cytokine activity, which were related to immune regulation and emerged as critical drivers of DDTC progression. The 4 immune cells between the high- and low-risk groups were markedly different, such as activated CD4 memory T cells and plasma cells. Drug sensitivity analysis indicated that 40 and 27 medications sensitive to high- and low-risk groups, respectively. A total of 41 drugs were predicted to have potential therapeutic effects, including omarigliptin, bepridil and bortezomib. Finally, qRT-PCR validation demonstrated that SLC26A4, KCNQ1, PMAIP1, DPP4, and NOX4 had expression trends consistent with public database results. Conclusion: This study identified 6 MDRGs (SLC26A4, SLC25A37, KCNQ1, PMAIP1, DPP4 and NOX4) associated with the prognosis of DDTC, providing valuable scientific insights and references for the targeted therapy and patient stratification of DDTC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.